Abstract:Abstract Relapse of malignancy remains a major cause of mortality among patients receiving allogeneic hematopoietic cell transplantation. We have previously published our center experience showing that patients who relapse after haplo had a worse 1 year post-relapse survival (PRS) compared to relapses after matched related or unrelated donors (17%, 46% and 40% respectively , p<0.05)(Solh et al, BMT 2016). We hypothesized at that time that relative lack of donor lymphocyte infusion (DLI) use following haplo relapses could have contributed to the difference in outcomes between donor types, and commenced incorporation of DLI into the management strategy for relapse after haplo transplantation. To assess this hypothesis, we investigated the post-relapse survival among consecutive 392 patients who received their haplo transplant at our center between January of 2008 and January of 2020 and assessed for factors contributing to improved PRS. Methods: A total of 392 patients who received their first haplo at our center were included in this analysis. Patient, disease, and transplant related factors were retrieved from our data base where they were prospectively entered. All transplants were performed in the outpatient setting with admissions reserved for complications that required inpatient care. GVHD prophylaxis for all patients was tacrolimus (till day 180), mycophenolate (stop at day 35) and cyclophosphamide 50mg/kg on days 3 and 4. Supportive care and GVHD management were per our programmatic standards. Endpoints included OS, DFS, NRM, relapse and post-relapse survival was assessed as survival from time of relapse. A landmark analysis for patients surviving more than 4 months post haplo was performed to assess for treatment factors affecting long term survival. Results: out of 392 transplant recipients, 109 experienced relapse of malignancy after receiving their first haplo transplant with a median time from transplant to relapse of 194 days (range 43-1268) and median age at relapse of 53 years (20, 74). The patient characteristics for relapsing patients were as follows: diagnosis (AML 37%, ALL 21%, MDS 20%, Lymphoma 16%), prior auto (16%), HCT-CI 0-2 (45%), Disease risk (high/very high 51%). Transplant characteristics included myeloablative regimen (42%), peripheral blood cell source (75%), HLA match (5/10 in 72%, 6/10 in 16%, 7/10 in 12%), and female donor -male recipient in 23%. Post relapse remission induction with disease specific therapy was given to 102 out of 109 patients. Additionally, seventeen patients received DLI (cell dose (1x10 5 to 5x10 6 CD3+ cells/kg)and 10 patients received a second transplant post relapse. 3 patients developed GVHD (aGCVD 2, moderate severe cGHVD 1) after DLI infusion. 1 year and 3-year endpoints for the whole 392 patients were OS (79% and 63%), DFS (70% and 56%), NRM (11% and 15%) and relapse (19% and 29%). 1-year and 3-year post-relapse survival were 37% and 19%. IN a landmark analysis at 4 months, receiving DLI had significantly better OS than no DLI p=0.015(figure 1). On a multivariable analysis for OS, factors associated with improved OS included time from transplant to relapse (>=1 year vs <6 months, HR 0.29, 95% CI 0.16-0.54, p<0.001)), DLI ( yes versus no, HR 0.61, p=0.015)) and patient sex ( male vs female, HR 1.74, 95% CI 1.07-2.81, p=0.025). In conclusion, some patients who relapse after Haplo with PTCY can still achieve long term remissions. The use of DLI in our experience is safe and contributed to improved survival. DLI should be considered in relapse management of haplo recipients. Figure 1 Figure 1. Disclosures Solh: Partner Therapeutics: Research Funding; BMS: Consultancy; ADCT Therapeutics: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy.

HAPLOIDENTICAL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS: THE ROLE OF PREVIOUS LINES OF THERAPY.

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Haploidentical Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Engraftment Failure after Unrelated and Autologous Cell Transplantation.

Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Refractory/Relapsed Acute Leukemia

Haploidentical Hematopoietic Stem Cell Transplantation Without In Vitro T-Cell Depletion For The Chronic Myeloid Leukemia: Improved Outcomes In Patients With Accelerated Phase And Blast Crisis Phase

S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

Long-term Follow-Up of Haploidentical Haematopoietic Stem Cell Transplantation in Paediatric Patients with High-Risk Acute Myeloid Leukaemia: Report from a Single Centre

Allogeneic Halpo-Identical Hematopoietic Stem Cell Transplantation For High-Risk Leukemia

Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-Csf)-primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience.

The Overview of the Short Term Curative Effects of HLA Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

Long‐term Follow‐up of Haploidentical Hematopoietic Stem Cell Transplantation Without in Vitro T Cell Depletion for the Treatment of Leukemia

[The Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation from Human Leukocyte Antigen-Identical Siblings in 95 Patients with Myelodysplastic Syndrome].

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse

The Clinical Analysis of Haploidentical Stem Cell Transplantation in Myelodysplastic Syndrome-Associated Acute Myeloid Leukemia

Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT

Treatment Of Acute Leukaemia With Unmanipulated Hla-Mis-Matched/Haploidentical Blood And Bone Marrow Transplantation

Long-term Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Leukemia

Outcome of Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/relapsed Acute Leukemia

Haploidentical Hematopoietic Sct May Be Superior to Conventional Consolidation/Maintenance Chemotherapy As Post-Remission Therapy for High-Risk Adult All

Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience.